{
    "Clinical Trial ID": "NCT00256243",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Chemotherapy With GM-CSF",
        "  Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour."
    ],
    "Eligibility": [
        "Eligibility Criteria:",
        "  Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented.",
        "  Patients must meet one of the criteria defined below (indicate one):",
        "  a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment.",
        "  b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease.",
        "  Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration.",
        "  Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal.",
        "  Patients must have a serum creatinine and bilirubin  the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT)  2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.",
        "  Patients must have an Absolute neutrophil count (ANC) of  1,500/\u03bcl and a platelet count of  100,000/\u03bcl. These tests must have been performed within 90 days prior to registration.",
        "  Patients must have a performance status of 0-2 by Zubrod criteria",
        "  Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential.",
        "  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Clinical Response Rate",
        "  Clinical response (CR): Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange.",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Chemotherapy With GM-CSF",
        "  Arm/Group Description: Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.",
        "  Overall Number of Participants Analyzed: 47",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  47 100.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/38 (0.00%)"
    ]
}